News

Over 61.1 patient-years of treatment experience, AOC 1001 was well tolerated in patients with DM1, with nausea and headache the most commonly reported adverse events.

Building on positive phase 1a data, ALX-001 demonstrated target engagement of mGluR5 receptor and maintained a safe profile across multiple doses.

Monepantel, a novel, potent, inhibitor of the mTOR pathway, was safe in patients with ALS, resulting in stabilized ALS Functional Rating Scale scores.

The director of the Adult Genetic Epilepsy Program at the University of Toronto talked about the critical issues experienced by patients who transition from pediatric to adult care in epilepsy. [WATCH TIME: 9 minutes]

The national medical advisor for the Parkinson's Foundation discussed the importance of continuous and ‘spaced’ physical therapy for Parkinson disease, highlighting the underutilization of this approach.

The delivery device is prefilled with the prescribed dose of Acthar Gel in 40- or 80-unit versions, and may help administration of the appropriate subcutaneous dose of Acthar Gel.

A recent analysis revealed a significant association between neuromyelitis optica spectrum disorder and connective tissue disease in patients diagnosed or suspected with Sjogren syndrome.

Comprised of more than 400 patients with SMA, results showed that wanting to be treated with all possible DMTs was the most common reason for combination therapy.

The neurologist and migraine expert at NYU Langone Health provided perspective on TBI Awareness Month and the importance of accurate detection and swift care for trauamatic brain injury. [WATCH TIME: 4 minutes]

A recent study showed that a short self-screening questionnaire boasted high sensitivity and specificity for identifying psychosis among patients with Parkinson disease.

Amanda Peltier, MD, a professor of neurology at Vanderbilt University Medical Center, spoke on current care needs for adults with neuromuscular disorders and the realistic ways to enhance clinical care going forward.

A meta-analysis on studies assessing FDA-approved dual orexin receptor antagonists for insomnia treatment highlighted a greater risk of adverse events, particularly for narcolepsy-like symptoms.

In recent news, the FDA has issued a complete response letter for Vanda Pharmaceuticals' tasimelteon for treating insomnia because of identified deficiencies and cannot be approved in its current form.

GA Depot, composed of extended-release microspheres administered intramuscularly, typically every 28 days, was expected to result in fewer injection site reactions than other glatiramer acetate products.

The instructor in the department of cell biology at Emory University provided context on a presentation at MDA 2024 regarding mutations in Kif5a in familial forms of amyotrophic lateral sclerosis. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

Catch up on any of the neurology news headlines you may have missed over the course of February 2024, compiled all into one place by the NeurologyLive® team.

The postdoctoral researcher in the department of neurology at Johns Hopkins School of Medicine discussed findings from a study on the impact of indole 3-lactate supplementation in animal models of multiple sclerosis. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Purple Day and epilepsy awareness.

Bijoy E. John, MD, founder and medical director of Sleep Wellness Clinics of America (Nashville) and Sleep Fix Academy, discussed the health risks associated with daylight saving time changes.

These finding suggest that even immune cells in the brain can play a significant role in the progression of neurodegenerative diseases like FA.

Neurology News Network for the week ending March 9, 2024. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 8, 2024.

Over the coming weeks, Amylyx will undergo heavy discussions with regulators and community members to decide the next best steps for AMX0035 after the agent failed to meet its primary end point in its latest study.

The director of the Comprehensive Care MS Center at Texas Tech University Health Sciences Center talked about findings from a subgroup analysis of Hispanic or Latin patients from the N-MOmentum trial presented at ACTRIMS Forum 2024. [WATCH TIME: 3 minutes]

The FDA will discuss TRAILBLAZER-ALZ 2, a large-scale phase 3 study that assessed the effects of donanemab in 1736 patients with early-stage Alzheimer disease over a 76-week period.

Mind Moments®, a podcast from NeurologyLive®, brings you an interview with Alcibiades Rodriguez, MD. [LISTEN TIME: 19 minutes]

New data from the phase 3b ENHANCE trial presented at ACTRIMS Forum 2024 demonstrated the smooth transition from intravenous anti-CD20 therapy to ublituximab in patients with multiple sclerosis.

The real-world, 3-year study is expected to include 30 males with SMA on risdiplam, an SMN2 splicing modifier, to assess fertility-related outcomes.

The staff neurologist at the Mellen Center for Multiple Sclerosis at Cleveland Clinic talked about findings from a real-world study assessing novel monoclonal antibodies in patients with NMOSD presented at ACTRIMS Forum 2024. [WATCH TIME: 4 minutes]